Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?: Letters

Diabetic Medicine

Volumn 26, Issue 8, 2009, Pages 834-835

  Ahluwalia, R ^a   Perkins, K ^a   Ewins, D ^a   Goenka, N ^a  

^a Countess of Chester NHS Foundation Trust ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLICLAZIDE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN; METFORMIN;

ADULT; BODY MASS; CASE REPORT; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSURIA; HUMAN; INSULIN BLOOD LEVEL; LETTER; MALE; MATURITY ONSET DIABETES MELLITUS; MUTATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHARMACOGENETICS; POSITIVE END EXPIRATORY PRESSURE; SLEEP APNEA SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; DIABETES MELLITUS, TYPE 2; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OBESITY; PEDIGREE; PEPTIDES; VENOMS;

EID: 70349377156     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02753.x     Document Type: Letter

References (4)

1. Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin. Diabet Med 2009 26 : 189 190.
2. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000 17 : 543 545.
3. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003 88 : 4897 4903.
4. Ahren B, Sorhede Winzell M, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol 2005 521 : 164 168.